[Form 4] ACADIA PHARMACEUTICALS INC Insider Trading Activity
Rhea-AI Filing Summary
ACADIA Pharmaceuticals EVP and CFO Mark C. Schneyer reported routine equity compensation activity involving restricted stock units and related tax sales. On April 5, 5,276 restricted stock units were exercised into 5,276 shares of common stock at a conversion price of $0.00 per share, increasing his direct holdings. The restricted stock units vest in four equal annual installments beginning April 5, 2023.
On April 7, 2,709 shares of common stock were sold at $22.20 per share, leaving Schneyer with 62,836 shares directly owned after the transactions. According to the disclosure, these mandatory sales were made to cover withholding taxes and related items in connection with the RSU vesting and are intended to comply with Rule 10b5-1(c) under the Exchange Act.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 2,709 | $22.20 | $60K |
| Exercise | Restricted Stock Units | 5,276 | $0.00 | $0.00 |
| Exercise | Common Stock | 5,276 | $0.00 | $0.00 |
Footnotes (3)
- F1. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
- F2. The mandatory sales reported in this Form 4 were made to cover withholding taxes and tax related items imposed by the Issuer in connection with the vesting of restricted stock units, and it is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c).
- F3. The restricted stock units vest in four equal annual installments beginning April 5, 2023.
Key Figures
Key Terms
Restricted Stock Units financial
withholding taxes financial
Rule 10b5-1(c) regulatory
derivative security financial
vesting financial
AI-generated analysis. How Rhea-AI works. Not financial advice.